

## Curriculum Vitae

**Frank V. Aguirre, M.D., F.A.C.C.**

### Office Address:

Prairie Cardiovascular Consultants, Ltd.  
 Baylis Building @ Memorial Medical Center  
 747 North Rutledge St.  
 Springfield, Illinois, 62702  
 Phone (217) 788-0706  
 FAX: (217) 757-7400

### Education:

June, 1973	Thomas Kelly High School Chicago, Illinois
May, 1977	Illinois Benedictine College Lisle, Illinois B.S., Biochemistry
May, 1980	Southern Illinois University Springfield, Illinois M.D.

### Postgraduate Training:

July 1980-June 1981	Internship Rush-Presbyterian St. Luke's Medical Center Rush University Chicago, Illinois
July 1981-June 1982	Medicine Internship St. Louis University Hospital/Clinic St. Louis, Missouri
July 1982-June 1983	Internal Medicine Residency St. Louis University Hospital St. Louis, Missouri
July 1983-June 1984	Chief Resident - Internal Medicine St. Louis City Hospital St. Louis University Medical Service St. Louis, Missouri
July 1985-June 1988	Clinical Cardiology Fellowship
July 1986-June 1987	Chief Fellow St. Louis University Medical Center St. Louis, Missouri

July 1988-June 1989  
Interventional Cardiology Fellow  
St. Louis University Medical Center  
St. Louis, Missouri

**Faculty Appointments:**

July 1984-June 1985  
Instructor of Medicine  
Department of Internal Medicine  
St. Louis County Hospital  
St. Louis University Medical Center  
St. Louis, Missouri

July 1988-June 1989  
Instructor of Medicine  
Division of Cardiology  
St. Louis University Medical Center  
St. Louis, Missouri

July 1989-June 1994  
Assistant Professor of Medicine  
Division of Cardiology  
St. Louis University Medical Center  
St. Louis, Missouri

July 1994-Jan 1998  
Associate Professor of Medicine (Tenure)  
Division of Cardiology  
Saint Louis University Health Sciences Center  
St. Louis, Missouri

November 2007-Present  
Clinical Professor of Medicine  
Southern Illinois School of Medicine  
Springfield IL.

July 1989-1992  
Associate Director, Coronary Care Unit  
Saint Louis University Health Sciences Center  
St. Louis, Missouri

February 1993-Jan 1998  
Director, Coronary Care Unit  
Saint Louis University Health Sciences Center  
St. Louis, Missouri

July 1996-Jan 1998  
Director, Interventional Cardiology  
Saint Louis University Health Sciences Center  
St. Louis, Missouri

January 1996-1998  
Director, Mobile Cardiac Catheterization Laboratory  
Carbondale Memorial Hospital  
Carbondale, Illinois

January 1999-Present  
Clinical Associate Professor of Medicine  
Southern Illinois University School of Medicine  
Springfield, IL

July 2003-June 2004      Acting Chief, Division of Cardiology  
Southern Illinois University School of Medicine  
Springfield, IL

July 2004-Present      Chief, Division of Cardiology  
Southern Illinois University School of Medicine  
Springfield, IL

**Medical School Committees:**

Jan 2002 – July 2006      Member, Springfield Committee for Research Involving  
Human Subjects (SCRIHS); Institutional Review Board  
Southern Illinois University School of Medicine  
Springfield, IL

September 2005 – Present      Member, Admissions Committee  
Southern Illinois University School of Medicine  
Springfield, IL 62794

July 2006 – Present      Co-director, Cardiopulmonary and Renal Curriculum  
2<sup>nd</sup> year Medical Students  
Southern Illinois University School of Medicine  
Springfield, IL

**Hospital Committees:**

July 1989- Jan 1994      Member, Special Care Review Committee  
Saint Louis University Health Sciences Center

July 1994-Jan 1999      Chairman, Special Care Review Committee  
Saint Louis University Health Sciences Center  
St. Louis, Missouri

July 1994-Jan 1999      Member, Quality Assurance Committee  
Saint Louis University Health Sciences Center  
St. Louis, Missouri

July 1995-July 1996      Member, Radiation Safety Committee  
Saint Louis University Health Sciences Center  
St. Louis, Missouri

July 1999 – Present      Board Member, Prairie Education and Research  
Cooperative (PERC research)  
Springfield, IL

Jan 1999-January 2007      Member, Pharmacy and Therapeutics Committee  
Memorial Medical Center  
Springfield, IL

Feb 2002 – January 2007      Member, Medical Economics and Outcome  
Memorial Medical Center  
Springfield, IL

Feb 2003 –Present	Member, Credential Committee Memorial Medical Center Springfield, IL
Feb 2003 –Jan 2007	Chairman, Credential Committee Memorial Medical Center Springfield, IL
January 2007 – Present	President-Elect, Medical Staff Memorial Medical Center Springfield, IL
January 2007 – Present	Member, Strategic Planning and Development Committee Memorial Medical Center Springfield, IL
January 2007 – Present	Member, Quality and Safety Management Committee Memorial Medical Center Springfield, IL
January 2007 – Present	Member, Executive Committee Memorial Medical Center Springfield, IL
February 2007 – Present	Medical Executive Committee Memorial Medical Center Springfield, IL
February 2007 – Present	Nominating Committee Memorial Medical Center Springfield, IL

### **Facility Privileges**

March 1998 - Present	Memorial Medical Center 701 N First Street Springfield, IL 62781
May 1999 – Present	St. John’s Hospital 800 E Carpenter Springfield, IL 62769
Jan 1998 – Present	St. Vincent’s Hospital 201 E Pleasant, Taylorville, IL 62568
01/98 to present	Abraham Lincoln Memorial Hospital 315 Eighth Street Lincoln, IL 62656

**Awards:**

1981	Intern of the Year Award Rush-Presbyterian St. Luke's Medical Center Chicago, Illinois
1982, 1983	Junior Student Teaching Award Saint Louis University Health Sciences Center St. Louis, Missouri
1986-1987	Cardiology Fellow of the Year Award Saint Louis University Health Sciences Center St. Louis, Missouri
2003	Alpha Omega Alpha Medical Honor Society

**Board Certification:**

December 1980	Federation Licensure Examination (FLEX)
September 1984	American Board of Internal Medicine
November 1987	Cardiovascular Diseases
November 2000	Interventional Cardiology

**Licensure:**

Missouri  
Illinois  
South Dakota (Inactive)

**Professional Organizations:**

Fellow	American College of Cardiology
Fellow	American Heart Association, Clinical Council of Cardiology
Fellow	Society for Cardiac Angiography and Interventions
Member	American College of Physicians
Member	American Medical Association

**GRANTS**

7/87-1/88	<b>Co-Investigator:</b> "A double-blind clinical study comparing the hemodynamic and electrocardiographic effects of Hexabrix and renografin-76 in selective coronary arteriography". Mallinckrodt, Inc., St. Louis, Missouri
8/88	<b>Co-Investigator:</b> "Bypass Angioplasty Revascularization Investigation (BARI)". NHLBI.

- 6/89-1/90 **Principal Investigator:** "A double-blind clinical study comparing the effects of Benadryl and Benadryl plus Axid for use as a premedication in patients undergoing coronary angiography". Mallinckrodt, Inc., St. Louis, Missouri
- 6/89-6/91 **Co-Investigator:** "A randomized, phase III placebo-controlled survival study of oral milrinone in patients with severe heart failure". Sterling Research Group, Sterling Drug, Inc.
- 4/89-10/89 **Co-Investigator:** "A multicenter prospective randomized placebo-controlled trial of Activase and heparin in patients with unstable angina (UNSA Trial)". Genentech, Inc., South San Francisco, CA
- 4/89-10/89 **Co-Investigator:** "Heparin-aspirin reperfusion trial (HART)". Genentech, Inc., South San Francisco, CA
- 2/88-7/90 **Principal Investigator:** "A pilot trial of late thrombolysis and delayed revascularization in (late) myocardial infarction (TAMI VI)". Genentech, Inc., South San Francisco, CA
- 10/89-1/93 **Co-Investigator:** "Thrombolysis in myocardial ischemia (TIMI III)". National Heart, Lung, and Blood Institute.
- 4/90-7/91 **Principal Investigator:** "A randomized trial comparing 7E3 monoclonal antibody and placebo in the treatment of patients with abrupt closure during angioplasty". Centocor, Inc., Malvern, PA
- 4/90-7/91 **Principal Investigator:** "A phase II multicenter trial of monoclonal antibody 7E3 Fab in patients with acute myocardial infarction (TAMI VIII)". Centocor, Inc., Malvern, PA
- 8/91-8/92 **Co-Investigator:** "Multicenter American Research Trial with cilazapril after angioplasty to prevent transluminal coronary obstruction and restenosis". Hoffman-LaRoche
- 8/91-11/93 **Co-Investigator:** "Intracoronary stenting for acute occlusion after coronary balloon angioplasty and as a primary treatment for coronary occlusion disease". Cook, Inc.
- 8/91-12/92 **Co-Investigator:** "A multicenter, open-label, ascending dose, safety and tolerability trial to compare the effects of CGP-39393 and heparin when given in conjunction with recombinant tissue-type plasminogen activator to patients with acute transmural myocardial infarction (TIMI V)". Ciba-Giegy, Summit, NJ
- 10/91-11/93 **Principal Investigator: COORDINATING CENTER** "t-PA heparin duration trial". Genentech, Inc., South San Francisco, CA
- 1/92-11/92 **Principal Investigator:** "EPIC - A phase III double-blind, placebo-controlled multicenter study of chimeric 7E3 Fab in patients undergoing high risk coronary angioplasty". Centocor, Inc., Malvern PA

- 8/93-4/94      **Principal Investigator:** "Adjunctive intralesional delivery of tissue plasminogen activator and heparin during angioplasty in unstable angina (UTOPIA)". Genentech, Inc., South San Francisco, CA
- 6/93-6/94      **Principal Investigator:** "A multicenter double-blind, randomized study to compare the safety and efficacy of B68967 with heparin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA)". Biogen, Inc. and Biogen, Ltd., Cambridge, MA
- 8/93-3/96      **Principal Investigator:** "A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin™ plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients (CARS)". Dupont Merck Pharmaceutical Co., Wilmington, DE
- 4/92-4/93      **Co-Investigator:** "A multicenter, open-label safety and tolerability trial to compare the effects of CGP-39393 and heparin when given in conjunction with streptokinase to patients with acute transmural myocardial infarction (TIMI VI)". Ciba-Giegy, Summit, NJ
- 7/93-7/94      **Co-Investigator:** "Thrombolysis and thrombin inhibition in acute myocardial infarction (TIMI 9)". Ciba-Giegy, Summit, NJ
- 1/94-11/94     **Principal Investigator:** "A randomized, double-blind efficacy and safety evaluation of two dosing regimens of integrelin versus placebo for reducing the complications of coronary angioplasty (IMPACT II)". Cor Therapeutics, Inc., South San Francisco, CA
- 3/94            **Principal Investigator:** "A randomized, double-blind parallel study to investigate the safety and clinical efficacy of MK-383 versus heparin in patients with unstable angina (PRISM)". Merck Research Laboratories, West Point, PA
- 3/94-12/95     **Principal Investigator:** "A phase III, randomized, double-blind, placebo-controlled trial evaluating 30-day and 6-month clinical outcome following percutaneous coronary intervention in patients treated with c7E3 fab bolus plus 12-hour infusion given with either standard-dose weight-adjusted or low-dose weight-adjusted heparin (EPILOG)". Centocor, Inc., Malvern, PA
- 2/96            **Principal Investigator:** "A multicenter, randomized trial evaluating 30-day and 6-month clinical outcome with three different treatment strategies in patients undergoing percutaneous coronary intervention (The EPILOG stent sub-study)". Centocor, Inc., Malvern, PA.
- 9/95            **Principal Investigator:** "A randomized, double-blind evaluation of the efficacy and safety of two dosing regimens of Integrilin™ versus placebo for reducing mortality and myocardial (re)infarction in patients with unstable angina or non-Q wave myocardial infarction (PURSUIT)". Cor Therapeutics.
- 1/96            **Principal Investigator:** "A Global Unstable Angina Registry and Treatment Evaluation (GUARANTEE)". Eli Lilly, Inc.

- 4/96 **Principal Investigator:** "A randomized, double-blind evaluation of the effects of Integrilin versus placebo on ex vivo platelet aggregation and GP IIb/IIIa receptor occupancy in patients with unstable angina or non-Q wave myocardial infarction (PERIGEE): A sub-study within PURSUIT study". Cor Therapeutics.
- 4/96 **Principal Investigator:** "RAPPORT: ReoPro™ in Acute Myocardial Infarction and Primary PTCA Organization and Randomized Trial (Protocol #C7E3 Fab (LY 314366)". Eli Lilly.
- 7/96 **Principal Investigator:** "A Randomized Evaluation of the Pharmacodynamics and Safety of a Range of Dosing Regimens of Integrilin versus Placebo in Patients Undergoing Percutaneous Coronary Interventions (Protocol #96-023) (PRIDE)". Cor Therapeutics.
- 9/97 **Principal Investigator:** "SCIMED Stent Comparative Restenosis Trial (SCORES)". Scimed.
- 12/98 **Co-Principal Investigator** (Clinical Coordinating Center): A Phase III Open-Label, Randomized, Multicenter Study of Expanded Utilization of Intravenous Beta-Blocker Therapy in Acute Ischemic Syndromes: The Esmolol in Acute Ischemic Syndrome (EMIT) Study Group, Ohmeda, Inc.
- 03/98 **Principal Investigator:** To compare in-hospital costs among low-risk patients undergoing elective/non-emergent percutaneous revascularization procedures who receive adjunctive platelet glycoprotein IIb/IIIa inhibition with either abciximab or eptifibatide (PRICE). Schering-Plough
- 3/98-3/99 **Co-Investigator:** Percutaneous Transmyocardial Laser Revascularization (PTMR) study.
- 5/98- 5/99 **Co-Investigator:** Sibrafiban vs Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-Acute Coronary Syndrome (SYMPHONY I) trial.
- 3/99- 5/99 **Co- Investigator:** Sibrafiban vs Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-Acute Coronary Syndrome (SECOND SYMPHONY) trial.
- 3/99- 4/00 **Principal Investigator:** Platelet Glycoprotein IIb/IIIa ReoPro vs. Integrilin Cost-Effectiveness (PRICE) trial: Evaluation in non-high risk patients undergoing percutaneous coronary intervention. COR Pharmaceuticals.
- 3/99-4/00 **Principal Investigator:** Phase II, Multicenter, Double-Blind, Placebo-Controlled, Dose Finding Study for Safety, Pharmacokinetics and Efficacy of Recombinant Fibroblast Growth Factor-2 (rFGF-2) in Subjects with Coronary Artery Disease (CAD). CHIRON Technologies.
- 3/00 - 4/00 **Principal Investigator:** Effect of citrate anticoagulation on platelet inhibition with a non-peptide platelet glycoprotein IIb/ IIIa antagonist during percutaneous coronary intervention: EFFORT trial. Merck, Inc.

- 11/00-01/01     **Principal Investigator:** Evaluation of catheter-based direct myocardial gene delivery in an ischemic porcine model. Boston Scientific, Inc.
- 01/01            **Co-Investigator:** Safety and efficacy of the Rabamycin-coated BX Velocity stent SIRUS. (Cordis).
- 4/02             **Co-Investigator:** “Saphenous Vein Graft Intervention Using Angio guard for Reduction of Distal Embolization (GUARD)”. Cordis, Warren NJ.
- 4/02             **Co-Investigator:** “Treatment of De Novo Coronary Disease Using Single Paclitaxel-Eluting Coronary Stent System (TAXUX IV)”. Boston Scientific, Natick MA.
- 12/02            **Principal Investigator:** “Clopidogrel for High Atherothrombotic Risk Ischemic Stabilization, Management and Avoidance (CHARISMA)”. Sanofi-Synthelabo, Malvern PA.
- 01/03            **Co-Investigator:** Low Molecular Weight heparin (Lovenox) for use in Trans Esophageal Echocardiography Guided Cardioversion of Patients with Atrial fibrillation (ACUTE II). Boston Scientific.
- 02/03            **Co-Investigator:** A randomized comparison of Angiomax (Bivalirudin) vs. Lovenox (Enoxaparin) in patients undergoing early invasive management for acute coronary syndrome w/out ST-segment elevation. (ACUITY). The Medicines Company.
- 09/03- Pres     **Co-Investigator:** Guidant - Nallamotheu - Advacent: National Registry to Advance Heart Health 2003 (ADVANCENT).
- 01/04- Pres     **Principal Investigator:** DUKE - Kinetics of Integrilin Limited by Obesity. A Multi-center prospective randomized single-blinded study designed to test the safety and efficacy of Eptifibatide in reducing ischemic complications in obese patients undergoing elective PCI. (KILO). 2003.
- 09/04- Pres     **Co-Investigator:** Aventis Inc.- A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II Study to Evaluate the Pharmacodynamics, the safety and tolerability, and the pharmacokinetics of several Intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673), in comparison to intravenous unfractionated heparin, in subjects undergoing non-urgent Percutaneous Coronary Intervention. (SEPIA) 2004.
- 09/04            **Co-Investigator:** Treatment of De Novo coronary Disease using a Single Paclitaxel-Eluting stent (TAXUS). Boston Scientific.
- 07/04            **Co-Investigator:** A multicenter, single-arm study of the Taxus Liberte’ SR stent for the treatment of patients with de novo coronary artery lesions (ATLAS) Boston Scientific

Frank V. Aguirre, M.D.

01/05-Pres

**Principal Investigator:** Guilford Pharmaceuticals, Inc.- A Randomized, Multicenter, Double-Blind, Abciximab-Controlled Study to Evaluate the Efficacy of Tirofiban versus Abciximab among Subjects Undergoing Percutaneous Coronary Intervention with Stent Placement Receiving Bivalirudin or Heparin. (TENACITY) 2004.

Frank V. Aguirre, M.D.

## EDITORIAL CONSULTANT

American Journal of Cardiology  
Catheterization and Cardiovascular Diagnosis  
Mayo Clinic Proceedings  
Circulation  
Journal of the American College of Cardiology  
Journal of American Medical Association  
Journal of Thoracic Surgery  
American Heart Journal

## EDITORIAL BOARD

American Heart Journal

## PRESENTATIONS

- 1990 American College of Cardiology Annual Scientific (New Orleans, LA) Meet the Experts: “Patient Management Following Thrombolysis”.
- 1996 European Society of Interventional Cardiology Annual Scientific Session 1996 (Madrid Spain): “Use of platelet Glycoprotein IIb/IIIa Inhibitor During Coronary Intervention”.
- 1996 Interventional Society of Hematology Annual Scientific Session 1996 (Nice, France): “Platelet Glycoprotein IIb/IIIa Inhibitor in Cardiovascular Diseases.”
- 1998 American Heart Association Annual Scientific Session (Dallas, TX): How-To-Session: “Early Diagnosis of Acute Myocardial Infarction”.
- 1999 American College of Cardiology/Society Cardiac Angiography and Intervention: Interventional Board Review Course (San Francisco, CA):  
Basic Science: Plaque Biology, Hematology, Pharmacology: Clotting Cascade  
Basic Science: Plaque Biology, Hematology, Pharmacology: Thrombolysis and Platelet Function  
Vasoactive Drugs, Antiarrhythmics and Anticoagulants: IV Thrombolytics vs Antiplatelet Agents  
Vasoactive Drugs, Antiarrhythmics and Anticoagulants: Antiarrhythmics and Hypolipidemics During and After Intervention.
- 2000 Society of Cardiovascular and Interventional Radiology 2000 Annual Scientific Session (San Antonio, TX): “An Interventional Odyssey: Blood pressure control: physiology and pharmacology and suggested uses of medications to raise and lower pressure”.
- 2000 American Heart Association Annual Scientific Session 2000 (New Orleans, LA): Meet the experts: “Adjunctive pharmacotherapy during percutaneous coronary intervention”.
- 2004 American College of Cardiology 52<sup>nd</sup> Annual Scientific Session (New Orleans, LA): Co-Chairman, Meet the Experts: “Acute Myocardial Infarction”.
- 2008 American College of Cardiology 57<sup>th</sup> Annual Scientific Session (Chicago, IL): Chairman, Meet the Experts: “Improving Door-to-Balloon Times”.

Frank V. Aguirre, M.D.

2008 American College of Cardiology 57<sup>th</sup> Annual Scientific Session (Chicago, IL): Chairman, Meet the Experts: "Variability in Response to Antiplatelets: Does it Matter and What Should I Do About It?"

## PUBLICATIONS

1. Greenberg RN, Kennedy DJ, Reilly PM, Luppen KL, Weinandt WJ, Bollinger MR, **Aguirre FV**, Kodesch F, Saeed MK. Treatment of bone, joint, and soft tissue infections with oral ciprofloxacin. *Antimicrobial Agents and Chemotherapy* 1987;31:151-155.
2. **Aguirre FV**, Buckingham TA. Signal-averaged electrocardiography for identification of patients with chronic coronary artery disease and sustained ventricular tachycardia. *Cardiol Board Review* 1987;4:21-28.
3. Kern MJ, **Aguirre F**, Shay Y, Gabliani G, Deligonul U, Bodet J, Vandormael M. Utility of continuous measurement of pulmonary artery oxygen saturation during episodic myocardial ischemia in patients. *J Intervent Cardiol* 1988; 1:131 – 136.
4. **Aguirre FV**, Pearson AC, Lewen MK, McClusky M, Labovitz AJ. Usefulness of Doppler echocardiography in diagnosis of congestive heart failure. *Am J Cardiol* 1989; 63:1098-1102.
5. Gudipati C, Kern MJ, **Aguirre FV**, Deligonul U. Papaverine-induced chest pain due to coronary vascular steal: demonstration with angiographic and intracoronary flow velocity measurements. *Am Heart J* 1989 Aug;118(2):404-407.
6. Serota H, Deligonul U, Lew B, Kern MJ, **Aguirre F**, Vandormael M. Improved method for transcatheter retrieval of intracoronary detached angioplasty guidewire segments. *Cathet Cardiovasc Diagn* 1989;17:248-251.
7. Fagan LF, **Aguirre FV**, Deligonul U, Kern MJ. Pseudodissection: negative contrast streaming from collateral flow branch mimicking coronary arterial dissection. *Cathet Cardiovasc Diagn*. 1989;Sep;18(1):15-17.
8. Kern MJ, Serota H, Callicot P, Deligonul U, Lew W, **Aguirre FV**, Lew B, Barner H, Willman V. Use of coronary arteriography in the pre-operative management of patients undergoing urgent repair of the thoracic aorta. *Am Heart J* 1990;119:143-148.
9. Kern MJ, Tatineni S, Gudipati C, **Aguirre F**, Ring ME, Serota H, Deligonul U. Regional coronary blood flow velocity and vasodilatory reserve in patients with angiographically normal coronary arteries. *Coro Artery Disease* 1990;1:579-589.
10. Kern MJ, Cohen M, Talley JD, Litvack F, Serota H, **Aguirre F**, Deligonul U, Bashore T. Early ambulation after 5 French diagnostic cardiac catheterization: results of a multicenter trial. *J Am Coll Cardiol* 1990;15:1475-1483.
11. Kern MJ, Gudipati C, Tatineni S, **Aguirre F**, Serota H, Deligonul U. Effect of abruptly increased intrathoracic pressure on coronary blood flow velocity in patients. *Am Heart J* 1990;119:863-870.
12. Serota H, Barth CW, Seuc CA, Vandormael M, **Aguirre F**, Kern MJ. Rapid identification of the course of anomalous coronary arteries: the "dot and eye" method. *Am J Cardiol* 1990;65:891-898.

13. Younis L, **Aguirre F**, Byers S, Walker H, Carrachi B, Peterson G. Perioperative and long-term prognostic value of intravenous dipyridamole thallium scintigraphy in patients with peripheral vascular disease. *Am Heart J* 1990;119:1287-1292..
14. **Aguirre FV**, Pearson AC, Lewen MK, Labovitz AJ. Identifying congestive heart failure patients whose systolic function is normal. *Congestive Heart Failure* 1990;7(9):19.
15. Kern MJ, Deligonul U, Serota H, Gudipati C, Ring M, Dressler F, **Aguirre F**. Acute combined aortic and mitral insufficiency during balloon catheter valvuloplasty for a third recurrence of critical aortic stenosis. *Am Heart J* 1990;120:1007-1011.
16. Kern MJ, Gudipati C, Tatineni, S, **Aguirre F**, Serota H, Deligonul U. Effect of abruptly increased intrathoracic pressure on coronary blood flow velocity in patients. *Am Heart J* 1990 Apr;119(4):863-70.
17. Serota H, Deligonul U, Lee W, **Aguirre F**, Kern MJ, Taussig SA, Vandormael M. Predictors of early (.6 months) mortality after coronary angioplasty in patients with severe left ventricular dysfunction. *Am J Cardiol* 1991;67:367-372.
18. Serota H, Kern MJ, Deligonul U, **Aguirre F**, Caralis DG. Ergonovine induced myocardial ischemia without epicardial coronary vasospasm: evidence for ischemia produced by small vessel vasoconstriction. *Am Heart J* 1991;121:1807-1809.112.
19. Hilton TC, Deligonul U, **Aguirre F**, Kern MJ. The "end-hole" pigtail catheter: an unusual complication of left ventriculography. *Cathet Cardiovasc Diagn* 1991;23:139-140.
20. Ofili E, Kern MJ, Tatineni S, Deligonul U, **Aguirre F**, Serota H, Labovitz AJ. Detection of coronary collateral flow by a Doppler-tipped guidewire during coronary angioplasty. *Am Heart J* 1991;122:221-225.
21. Hilton TC, **Aguirre F**, Greenwalt T, Janosik DL, Kern MJ. Successful treatment of complex ventricular arrhythmias with percutaneous transluminal coronary angioplasty. *Am Heart J* 1991;122:230-231.
22. Kern MJ, Talley JD, Deligonul U, Serota H, **Aguirre F**, Gudipati C, Ring M, Joseph A, Yussman ZA, Kulick D, Salinger M. Preliminary experience with 5 French diagnostic catheters as guiding catheters for coronary angioplasty. *Cathet Cardiovasc Diagn* 1991;22: 60-63.
23. **Aguirre FV**, Pedersen W, Castello R, Deligonul U, Gudipati C, Serota H, Labovitz AJ, Kern MJ. The effects of high (sodium meglumine diatrizoate, Renografin-76<sup>TM</sup>) and low osmolar (sodium meglumine ioxaglate, Hexabrix<sup>TM</sup>) radiographic contrast media on diastolic function during left ventriculography in patients. *Am Heart J* 1991;121:848-857.
24. Kern MJ, Deligonul U, Tatineni S, Serota H, **Aguirre F**, Hilton TC. Intravenous adenosine: continuous infusion and low dose bolus administration for determination of coronary vasodilatory reserve in patients with and without coronary artery disease. *J Am Coll Cardiol* 1991;18:718-729.
25. Ofili E, Kern MJ, Tatineni S, Deligonul U, **Aguirre F**, Serota H, Labovitz AJ. Detection of coronary collateral flow by a Doppler-tipped guidewire during coronary angioplasty. *Am Heart J* 1991;122:221-225.

26. **Aguirre FV**, Kern MJ, Hsia J, Janosik D, Greenwalt T, Ross AM, Chaitman BR. Importance of myocardial infarct artery patency on the prevalence of ventricular arrhythmia and late potentials after thrombolysis in acute myocardial infarction. *Am J Cardiol* 1991;68: 1410-1416.
27. Hilton TC, **Aguirre FV**, Greenwalt T, Janosil DL, Kern MJ. Successful treatment of complex ventricular arrhythmias with percutaneous transluminal coronary angioplasty. *Am Heart J* 1991 Jul;122(1 Pt 1):230-1.
28. Kern MJ, **Aguirre FV**. Ionic vs nonionic contrast agents. *Cathet Cardiovasc Diagn* 1991 Sep;24(1):71-2.
29. Kern MJ, Roth RA, **Aguirre FV**, Beauman G, Vogel R. Effect of viscosity and iodine concentration of nonionic radiographic contrast media on coronary arteriography in patients. *Am Heart J* 1992;123:160-165.
30. Tatineni S, Kern MJ, **Aguirre F**. The effect of ergonovine on coronary vasodilatory reserve in patients with angiographic normal coronary arteries. *Am Heart J* 1992;123: 617-620.
31. Kern MJ, **Aguirre F**. Coronary blood flow alternans: a unique examination of coronary physiology and influence of intra-aortic balloon pumping. *Am Heart J* 1992;123:1369-1373.
32. Tatineni S, Kern MJ, **Aguirre F**, Donohue T, Bell C. Angiographic identification of malpositioned balloon catheters during mitral valvuloplasty. *Cathet Cardiovasc Diagn* 1992; 25:235-240.
33. Flynn MS, Kern MJ, **Aguirre F**, Donohue T, Bach R. Management of a complicated pericardiocentesis. *Cathet Cardiovasc Diagn* 1992;25:249-252.
34. Donohue T, **Aguirre F**, Miller L, Kern MJ. Angiographic and intracoronary flow velocity reversal in a transplanted heart: a common etiology for an uncommon condition. *Am Heart J* 1992;123:1374-1377.35. Tatineni S, Kern MJ, **Aguirre F**, Donohue T, Bach R, Bell C. The usefulness of a tracking catheter in complex coronary angioplasty. *Cathet Cardiovasc Diagn* 1992;27:75-81.
36. Donohue T, Kern MJ, Wolford T, Bach R, **Aguirre F**, Miller L. The effects of epicardial coronary spasm on intracoronary flow velocity and pressure gradient in a patient after cardiac transplantation. *Am Heart J* 1992;124:1645-1648.
37. Castello R, Lenzen P, **Aguirre FV**, Labovitz AJ. Quantitation of mitral regurgitation by color flow Doppler and transesophageal echocardiography: correlation with cardiac catheterization. *J Am Coll Cardiol* 1992;19:1516-1521.
38. Sharma A, Kern MJ, Callicoa P, **Aguirre F**, Labovitz A, Willman VL. Severe subpulmonic outflow obstruction caused by aneurysm of the membranous ventricular septum: diagnosis by transesophageal echocardiography. *Am Heart J* 1992;123:810-814.
39. Topol EJ, Califf RM, Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O'Brien M, Schwaiger M, **Aguirre FV**, Young S, Popma JJ, Sigmon KN, Lee KL, Ellis SG, the Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group (TAMI VI). A randomized trial of late reperfusion therapy for acute myocardial infarction. *Circulation* 1992;85:2090-2099.

40. Tatineni S, Kern MJ, Deligonul U, **Aguirre F**. The effects of ionic and non-ionic radiographic contrast media on coronary hyperemia in patients during coronary angiography. *Am Heart J* 1992;123:621-627.
41. Hsia J, Kleiman N, **Aguirre FV**, Chaitman BR, Roberts R, Ross AM. Heparin-induced PTT prolongation after thrombolysis: relationship to coronary patency. *J Am Coll Cardiol* 1992;20:31-35.
42. Castello R, Lenzen P, **Aguirre F**, Labovitz A. Variability in the quantitation of mitral regurgitation by color flow Doppler: comparison between transthoracic and transesophageal studies. *J Am Coll Cardiol* 1992;20:433-438.
43. **Aguirre FV**, Dressler FA, Wolford T, Donohue TJ, Bach R, McBride L, Galindo LP, Kern MJ. Emergent saphenous vein graft stent after unsuccessful balloon angioplasty: clinical, angiographic, and histologic findings. *Am Heart J* Apr;1993;125(4):1161-1164.
44. Bell CA, Kern MJ, **Aguirre FV**, Donohue T, Bach R, Wolford T, Penick D, Ofili E, Miller L. Superior accuracy of anatomic positioning with echocardiographic-over fluoroscopic-guided endomyocardial biopsy. *Cathet Cardiovasc Diagn* 1993 Apr;28(4):291-294.
45. Kern MJ, Flynn MS, **Aguirre FV**, Donohue TJ, Bach RG, Caracciolo EA. Application of intracoronary flow velocity for detection and management of ostial saphenous vein graft lesions. *Cathet Cardiovasc Diagn* 1993;30:5-10.
46. Bach RG, Kern MJ, Donohue TJ, **Aguirre FV**, Caracciolo EA. Comparison of phasic blood flow velocity characteristics of arterial and venous coronary artery bypass conduits. *Circulation* 1993;88[part 2]:133-140.
47. Flynn MS, Kern MJ, Donohue TJ, **Aguirre FV**, Bach RG, Caracciolo EA. Alterations of coronary collateral blood flow velocity during intraaortic balloon pumping. *Am J Cardiol.* 1993 Jun 15;71(16):1451-1454.
48. Kern MJ, Wolford T, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Flynn MS. Quantitative demonstration of dipyridamole-induced coronary steal and alteration by angioplasty in man: analysis by simultaneous, continuous dual Doppler spectral flow velocity. *Cathet Cardiovasc Diagn.* 1993 Aug;29(4):329-334.
49. Bach RG, Kern MJ, Bell C, Donohue T, **Aguirre F**. Clinical application of coronary flow velocity for stent placement during coronary angioplasty. *Am Heart J* 1993;125: 873-877.
50. Bell C, Kern MJ, **Aguirre F**, Miller L, Bach R, Donohue T, Dressler F. Coronary atherectomy complicated by coronary embolus in a cardiac transplant recipient. *Am Heart J* 1993;125:1172-1175.
51. Kern MJ, Donohue T, Bach R, **Aguirre F**, Bell C. Monitoring cyclical coronary blood flow alterations following coronary angioplasty for stent restenosis using a Doppler guidewire. *Am Heart J* 1993;125:1159-1160.
52. Kern MJ, **Aguirre F**, Bach R, Donohue T, Segal J. Augmentation of coronary blood flow by intra-aortic balloon pumping in patients after coronary angioplasty. *Circulation* 1993;87:500-511.

53. Kern MJ, **Aguirre FV**, Tatineni S, Penick D, Serota H, Donohue T, Walter K. Enhanced coronary blood flow velocity during intraaortic balloon counterpulsation in critically ill patients. *J Am Coll Cardiol.* 1993 Feb;21(2):359-368.
54. **Aguirre FV**, Bach R, Donohue TJ, Caracciolo E, Kern MJ. Rotational coronary ablation: more grist for the interventional mill? Editorial. *J Am Coll Cardiol.* 1993 Feb;21(2):296-297.
55. Ofili EO, Kern MJ, Labovitz AJ, St. Vrain JA, Segal J, **Aguirre FV**, Castello R. Analysis of coronary blood flow velocity dynamics in angiographically normal and stenosed arteries before and after endolumen enlargement by angioplasty. *J Am Coll Cardiol.* 1993 Feb;21(2):308-316.
56. Donohue TJ, Kern MJ, **Aguirre FV**, Bach RG, Wolford T, Bell CA, Segal J. Assessing the hemodynamic significance of coronary artery stenoses: analysis of translational pressure-flow velocity relations in patients. *J Am Coll Cardiol* 1993;22:449-458.
57. Bach RG, Kern MJ, **Aguirre FV**, Donohue TJ, Bell C, Penick D. Effect of percutaneous transluminal coronary angioplasty balloon compliance on angiographic and clinical outcomes. *Am J Cardiol* 1993;72:904-907.
58. TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. *Circulation* 1993;87:38-52.
59. Taylor HA, Chaitman BR, Rogers WJ, Kern MJ, Terrin ML, **Aguirre FV**, Sopko G, McMahon R, Ross RN, Bovill EC. Race and prognosis after myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. *Circulation* 1993 Oct;88(4 Pt 1):1484-94.
60. EPIC Principal Investigators. Randomized, Double-blind evaluation of a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor for preventing ischemic complications of high risk angioplasty. *N Engl J Med* 1994;330:956-961.
61. Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Ofili EO. Quantitating coronary collateral flow velocity in patients during coronary angioplasty using a Doppler guidewire. *Am J Cardiol/* 1993 May 20;71(14):34D-40D.
62. Kern MJ, Donohue TJ, **Aguirre FV**, Bach RG, Caracciolo EA, Ofili E, Labovitz AJ. Assessment of angiographically intermediate coronary artery stenosis using the Doppler flowwire. *Am J Cardiol/* 1993 May 20;71(14):26D-33D.
63. Taylor HA, Chaitman BR, Rogers WJ, Kern MJ, Terrin ML, **Aguirre FV**, Sopko G, McMahon R, Ross RN, Bovill EC and the TIMI investigators. Race and prognosis after myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. *Circulation* 1993;88[part I]:1484-1494.
64. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, **Aguirre FV**, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the thrombolysis and angioplasty in myocardial infarction (TAMI 8) pilot study. *J Am Coll Cardiol* 1993;22:381-389.

65. Flynn MS, Kern MJ, **Aguirre FV**, Caracciolo EA, Donohue TJ, Bach RG. Facilitated drainage of pericardial effusion with a fenestrated pigtail catheter and sheath system. *Cathet Cardiovasc Diagn* 1993;30:73-75.
66. Flynn MS, **Aguirre FV**, Donohue TJ, Bach RG, Caracciolo EA, Kern MJ. Conservative management of guidewire coronary artery perforation with pericardial effusion during angioplasty for acute inferior myocardial infarction. *Cathet Cardiovasc Diagn* 1993;29:285-288.
67. Cox DA, Rogers WJ, **Aguirre FV**, Forman S, Solomon R, Zaret BL and the Thrombolysis in Myocardial Infarction Investigators. Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction. *Am J Cardiol* 1994;73(11):729-736.
68. Kern MJ, **Aguirre FV**, Bach RG, Donohue TJ, Caracciolo EA. Restoration of normal phasic flow velocity after multiple coronary artery stent placement. *Am Heart J* 1994;127: 204-207.
69. **Aguirre FV**, Kern MJ, Bach R, Donohue T, Caracciolo E, Flynn MS, Wolford T. Intraaortic balloon pump support during high-risk coronary angioplasty. *Cardiology*. 1994; 84(3):175-186.
70. Kern MJ, **Aguirre FV**, Donohue TJ, Bach RG, Caracciolo EA, Flynn MS. Coronary flow velocity monitoring after angioplasty associated with abrupt reocclusion. *Am Heart J*. 1994 Feb;127(2):436-438.
71. Miller DD, Donohue TJ, Younis LT, Bach RG, **Aguirre FV**, Wittry MD, Goodgold HM, Chaitman BR, Kern MJ. Correlation of pharmacologic <sup>99m</sup>Tc-sestamibi myocardial perfusion imaging with poststenotic coronary flow reserve in patients with angiographically intermediate coronary artery stenoses. *Circulation*. 1994 May;89(5):2150-2160.
72. **Aguirre FV**. Editorial. The cost of an open infarct-related artery: comparison of treatment modalities in the reperfusion era. *Mayo Clin Proc*. 1994 Jan;69(1):87-89.
73. **Aguirre FV**, McMahon RP, Mueller H, Kleiman NS, Kern MJ, Desvigne-Nickens P, Hamilton WP, Chaitman BR, for the TIMI II Investigators. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy: results from the TIMI II study. *Circulation*. 1994 Jul;90(1):78-86.
74. Flynn MS, Caracciolo EA, Bach RG, Donohue TJ, **Aguirre FV**, Kern MJ. Approach to total occlusion of an aorto-ostial "Y" saphenous vein graft with anterior descending graft limb stenosis by serial balloon angioplasty and elective stent deployment. *Cathet Cardiovasc Diagn*. 1994 Oct;33(2):139-144.
75. Caracciolo EA, Kern MJ, Collis WC, Bach RG, Donohue TJ, Mechem C, **Aguirre FV**. Improved left ventriculography with the new 5F helical-tip Halo catheter. *Am Heart J* 1994;128:724-732.
76. Kern MJ, **Aguirre FV**, Donohue TJ, Bach RG, Caracciolo EA, Flynn MS, Wolford T, Moore JA. Continuous coronary flow velocity monitoring during coronary interventions: velocity trend patterns associated with adverse events. *Am Heart J*. 1994 Sep;128(3):426-434.

77. **Aguirre F.** Post-procedural patient management: prevention and management of bleeding complications. *J Invas Cardiol* 1994;6:34A-37A.
78. Cox DA, Rogers WJ, **Aguirre FV**, Forman S, Solomon R, Zaret BL. Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. *Am J Cardiol.* 1994 Apr 15;73(11):729-36.
79. **Aguirre FV**, Younis LT, Chaitman BR, Ross AM, McMahon RP, Kern MJ, Berger PB, Sopko G, Rogers WJ, Shaw L, Knatterud G, Braunwald E for the TIMI II Investigators. Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis: results from the TIMI II study. *Circulation.* 1995 May 15;91(10):2541-2548.
80. **Aguirre FV**, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. *Circulation* 1995 Jun 15;91(12):2882-2890.
81. Dolan MS, Castello R, St. Vrain JA, **Aguirre FV**, Labovitz AJ. Quantitation of aortic regurgitation by Doppler echocardiography: a practical approach. *Am Heart J* 1995; 129(5):1014-1020.
82. Tron C, Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Moore JA. Comparison of quantitative angiographically derived and measured translesion pressure and flow velocity in coronary artery disease. *Am J Cardiol.* 1995 Jan 15;75(2):111-117.
83. Kern MJ, Donohue TJ, **Aguirre FV**, Bach RG, Caracciolo EA, Wolford T, Mechem C, Flynn MS, Chaitman B. Clinical outcome of deferring angioplasty in patients with normal translesional pressure-flow velocity measurements. *J Am Coll Cardiol.* 1995 Jan;25(1):178-187.
84. Kern MJ, Donohue TJ, Bach RG, Caracciolo EA, **Aguirre FV**, Labovitz AJ. Hemodynamic significance of coronary jet velocity in patients: limitations of the Bernoulli equation in small conduits. *Am Heart J.* 1995 May;129:887-894.
85. Schaff HV, Rosen AD, Shemin RJ, Leclerc Y, Wareing TH, **Aguirre FV**, Sopko G, VanderSalm TJ, Loop FD and BARI investigators. Clinical and operative characteristics of patients randomized to coronary artery bypass surgery in the bypass angioplasty revascularization investigation (BARI). *Am J Cardiol.* 1995 Mar 23;75(9):18C-26C.
86. Tron C, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Wolford TL, Miller DD, Kern MJ. Comparison of pressure-derived fractional flow reserve with poststenotic coronary flow velocity reserve for prediction of stress myocardial perfusion imaging results. *Am Heart J.* 1995 Oct;130(4):723-733.
87. Moliterno DJ, Califf RM, **Aguirre FV**, Anderson K, Sigmon KN, Weisman HF, Topol EJ for the EPIC study investigators. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (The EPIC Trial). *Am J Cardiol.* 1995 Mar 15;75(8):559-562.

88. Ofili EO, Kern MJ, St. Vrain JA, Donohue TJ, Bach R, Al-Joundi B, **Aguirre FV**, Castello R, Labovitz AJ. Differential characterization of blood flow, velocity and vascular resistance between proximal and distal normal epicardial human coronary arteries: analysis by intracoronary Doppler spectral flow velocity. *Am Heart J*. 1995 Jul;130(1):37-46.
89. Gurbel PA, Navetta FI, Bates ER, Muller DW, Tenaglia AN, Miller MJ, Muhlstein B, Hermiller JB, Davidson CJ, **Aguirre FV**, Beauman GJ, Berdan LG, Leimberger JD, Bovill EG, Christenson RH, Ohman EM. Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. *Cathet Cardiovasc Diagn*. 1996 Apr;37(4):382-391.
90. Bach RG, Kern MJ, Donohue TJ, Caracciolo EA, **Aguirre FV**, Moore JA. Dynamic systolic coronary flow reversal and hyperemia in left anterior descending coronary blood flow velocity during Valsalva maneuver in a patient with hypertrophic cardiomyopathy. *Cathet Cardiovasc Diagn*. 1995 Jan;34(1):67-71.
91. Kern MJ, Piek JJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ. Collateral flow velocity alterations in the supply and receiving coronary arteries during angioplasty for total coronary occlusion. *Cathet Cardiovasc Diagn*. 1995 Feb;34(2):167-74.
92. Bach RG, Donohue TJ, Caracciolo EA, Wolford T, **Aguirre FV**, Kern MJ. Quantification of collateral blood flow during PTCA by intravascular Doppler. *Eur Heart J*. 1995 Oct;16 Suppl J:74-7.
93. Miller DD, Craig FE, Dressler FA, **Aguirre FV**, Farrar MA, Breland CM, Donohue TJ, Kern MJ, Bach RG. Immunohistochemical characterization of immune cell composition and cytokine receptor expression in human coronary atherectomy tissue. *Coron Artery Dis*. 1995 Dec;6(12):965-72.
94. **Aguirre FV**, Topol EJ, Anderson KM, Kleiman NS, Weisman HF, FitzPatrick SE, Califf RM. Clinical benefit within patient subgroups receiving c7E3 Fab (Abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. *J Invas Cardiol*. 1996;8(suppl B):21B-29B.
95. Donohue TJ, Miller DD, Bach RG, Tron C, Wolford T, Caracciolo EA, **Aguirre FV**, Younis LT, Chaitman BR, Kern MJ. Correlation of post-stenotic hyperemic coronary flow velocity and pressure with abnormal stress myocardial perfusion imaging in coronary artery disease. *Am J Cardiol* 1996;77:948-954.
96. Kern MJ, Caracciolo EA, **Aguirre FV**, Bach RG, Miller LW, Mechem C, Donohue TJ. Variations in normal coronary vasodilatory reserve stratified by artery, gender, heart transplantation and coronary artery disease. *J Am Coll Cardiol* 1996;28:1154-1160.
97. Khoury AF, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ, Wolford T, Mechem C, Herrmann SC, Kern MJ. Influence of percutaneous transluminal coronary rotational atherectomy with adjunctive percutaneous transluminal coronary angioplasty on coronary blood flow in patients. *Am Heart J* 1996;131:631-638.
98. Kern MJ, Moore JA, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ, Wolford T, Khoury AF, Mechem C. Determination of angiographic (TIMI grade) blood flow by intra-coronary Doppler flow velocity during acute myocardial infarction. *Circulation* 1996; 94:1545-1552.

99. Tron C, Donohue TJ, Bach RG, Wolford T, Carcciolo EA, **Aguirre FV**, Khoury A, Kern MJ. Differential characterization of human coronary collateral blood flow velocity. *Am Heart J* 1996;132:508-515.
100. Kern MJ, **Aguirre FV**. Improved technique for use of half-stents remounted on a stent delivery system. *Cathet Cardiovasc Diagn* 1997;40:335.
101. Kern MJ, Dupouy P, Drury JH, **Aguirre FV**, Aptecar E, Bach RG, Caracciolo EA, Donohue TJ, Dubois-Rande J, Geschwind HJ, Mechem CJ, Kane G, Teiger E, Wolford TL. Role of coronary artery lumen enlargement in improving coronary blood flow after balloon angioplasty and stenting: a combined intravascular ultrasound Doppler flow and imaging study. *J Am Coll Cardiol* 1997;29:1520-1527.
102. Bitar SR, **Aguirre FV**, McBride L, Munroe C, Kern MJ. Characterization of intra-arterial flow velocity within left coronary to pulmonary artery fistula. *Cathet Cardiovasc Diagn* 1997;41:208-212.
103. **Aguirre FV**, Werth D, Gudipati C, Lewen MK, Pedersen WR, Johnson WB, Hamilton W, Gibson P, Stonner S, Flynn MS, Armbruster R, Al-Joundi B, Vermilya S, Chaitman BR, for the t-PA-Heparin Duration Investigators. Clinical and angiographic outcomes among patients receiving 24 vs 72 hours of intravenous heparin following accelerated dosing of recombinant tissue plasminogen activator in acute myocardial infarction. *Circulation* (In press, 1999)
104. Craig WR, **Aguirre FV**, Kern MJ. Unsuspected articulation side strut extension during stenting in a tortuous right coronary artery. *Cathet Cardiovasc Diagn* 1997 Dec;42(4):417-9.
105. Anderson HV, Gibson RS, Stone PH, Cannon CP, **Aguirre FV**, Thompson B, Knatterund GL, Braunwald E. Management of unstable angina pectoris and non-Q-wave acute myocardial infarction in the United States and Canada (the TIMI III Registry). *Am J Cardiol* 1997 Jun 1;79(11):1441-6.
106. Lincoff AM, Califf RM, Anderson KM, Weisman HF, **Aguirre FV**, Kleiman NS, Harrington RA, Topol EJ. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c78E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators Evaluation of 7E3 in Preventing Ischemic Complications. *J Am Coll Cardiol* 1997 Jul;30(1):149-56.
107. Chaitman BR, Rosen AD, Williams DO, Bourassa MG, **Aguirre FV**, Pitt B, Rautaharju PM, Rogers WJ, Sharaf B, Attubato M, Hardison RM, Srivatsa S, Kouchoukos NT, Stocke K, Sopko G, Detre K, Frye R. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. *Circulation* 1997 Oct 7;96(7):2162-70.
108. Khan MM, Ellis SG, **Aguirre FV**, Weisman HF, Wilderman N, Califf RM, Topol EJ, Kleiman NS. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. *J Am Coll Cardiol* 1998 Jan;31(1):31-6.

109. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, **Aguirre FV**, Anderson KM, Weisman HF, Califf RM, Topol EJ; for the EPILOG investigators. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin. Evidence for a complex interaction in a multicenter trial. *Circulation* 1998 May 19;97(19):1912-1920.
110. Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, **Aguirre FV**, Sigmon KN, Timmis GC, Gilchrist IC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, Lincoff AM, Tchong JE, Califf RM, Topol EJ, for the IMPACT II investigators. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. *J Am Coll Cardiol* 1998 Jun;31(7):1518-24.
111. Stikovac MM, El-Badry MA, Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Craig WR, Bitar S, Wolford CJ, Miller DD. Comparison of relative coronary doppler flow velocity reserve to stress myocardial perfusion imaging in the assessment of intermediate coronary artery stenosis. (Submitted)
112. Every NR, Cannon C, Granger C, Moliterno D, **Aguirre FV**, French W, Talley D, Booth J, Ferguson J for the GUARANTEE Investigators. The influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina. *J Am Coll Cardiol* 1998 Aug;32(2):387-92.
113. Blankenship JC, Hellkamp AS, Demko SL, **Aguirre FV**, Topol EJ, Califf RM, for the EPIC Investigators. Vascular access site complications after percutaneous coronary intervention with glycoprotein IIb/IIIa receptor inhibitor therapy in the EPIC trial. *J Am Coll Cardiol* 1998 Jan 1;31(1):36-40
114. Kern MJ, Puri S, Bach RG, Donohue TJ, Dupouy P, Caracciolo EA, Craig WR, **Aguirre F**, Aptekar E, Wolford TL, Mechem CJ, Dubois-Rande JL. Abnormal coronary flow velocity reserve after coronary artery stenting in patients: Role of relative coronary reserve to assess potential mechanisms. (Submitted)
115. Kern MJ, **Aguirre FV**, Caracciolo EA, Bach RG, Donohue TJ, Lasorda D, Ohman M, Schnitzler RN, King DL, Ohley WJ, Grayzel J. Hemodynamic effects of new intra-aortic balloon counterpulsation timing methods in patients: a multicenter evaluation. *Am Heart J* 1999;137:1129-36.
116. **Aguirre FV**, Topol EJ, Simoons ML, Ferguson JJ, Lincoff AM, Tchong JE, Fitzpatrick SE, Leimberger JD, Blankenship J, van den Brandt M, Kern MJ, Kleiman NS, Kereiakes DJ, Rutsch W, Califf RM for the EPIC and CAPTURE Investigators. Impact of contrast media choice on clinical outcomes of percutaneous coronary interventions: analysis of abciximab trials of angioplasty. *J Am Coll Cardiol* (Submitted 3/99).
117. Mishkel GJ, **Aguirre FV**, Ligon RW, Rocha-Singh KJ, Luore CL for Prairie Cardiovascular Consultants, Ltd. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. *J Am Coll Cardiol* 1999 Dec; 34(7): 1884-90.
118. Scirica BM, Moliterno DJ, Every NR, Anderson HV, **Aguirre FV**, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Cannon CP. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. *Am Heart J.* 1999 Dec; 138(6 pt 1): 1065-72.

119. Scirica BM, Moliterno DJ, Every NR, Anderson HV, **Aguirre FV**, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Cannon CP. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. *Am J Cardiol.* 1999 Nov 15;84(10):1145-50.
120. Gilchrist IC, Connor J, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, Kleiman NS, Talley D, **Aguirre FV**, Davidson C, Runyon J, Tchong JE. Pharmacodynamics and Pharmacokinetics of higher-dose, double-bolus eptifibatid in percutaneous coronary intervention. *Circulation* 2001;104:406-411
121. The PRICE investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) trial. *Am Heart J* 2001;141:402-9.
122. Sekaran NK, Moliterno DJ, Ferguson JJ, Every N, Anderson HV, **Aguirre FV**, French WJ, Sapp S, Booth JE, Granger CB, Cannon CP. AHot@ unstable angina - is it worse than subacute unstable angina? Results from the GUARANTEE registry. (Submitted)
123. Nguyen CM, Tchong JE, **Aguirre FV**, Berger PB, Califf RM, Cohen D, Gibson M, Gold H, Herrmann HC, Jennings LK, Kleiman NS, Moliterno DJ, Peterson E, Phillips DR, Saucedo J, Schneider D, Sharma S, White HD, Yeunt A, Harrington RA. Pharmacodynamic considerations with glycoprotein IIb/IIIa receptor antagonists (Accepted by American Journal of Cardiology)
124. Scirica BM, Cannon CP, Gibson CM, Murphy SA, Moliterno DJ, Anderson HV, **Aguirre FV**, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Braunwald E. Assessing the Effect of Publication of Clinical Guidelines on the Management of Unstable Angina and Non-ST Elevation Myocardial Infarction in The TIMI III (1990-1993) and the Guarantee (1995-1996) Registries. *Critical Pathways in Cardiology* 2002; 1:3:150-158.
125. Schneider DJ, Herrmann HC, Lakkis N, **Aguirre FV**, Wan Y, Aggarwal A, Kabbani SS, DiBattiste PM. Enhanced Early Inhibition of Platelet Aggregation with an Increased Bolus of Tirofiban. *American Journal of Cardiology* 2002 Dec 15; 90(12):1421-3 (Accepted by American Journal of Cardiology).
126. **Aguirre FV**, Schneider DJ, Herrmann HC, Lakkis N, Lo MW, Yin KC, Aggarwal A, Kabbani SS, DiBattiste PM. Increased Concentrations of Tirofiban in Blood and Their Correlation With Inhibition of Platelet Aggregation After Greater Bolus Doses of Tirofiban. *The American Journal of Cardiology* Vol 91 February 1, 2003.
127. **Aguirre FV**, Gill JB. Increasing benefit, reducing risk: focusing on hemorrhagic complications in percutaneous coronary intervention. *Journal of Invasive Cardiology* 2002 Apr; 14 Suppl B:48B-54B.
128. El-Shafei A, Chiravuri R, Stikovac MM, El-Badry MA, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Bitar S, Wolford TL, Miller DD, Kern MJ. Comparison of relative coronary Doppler flow velocity reserve to stress myocardial perfusion imaging in patients with coronary artery disease. *Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions* 2001 June; 53 (2):193-201.

Frank V. Aguirre, M.D.

129. **Aguirre FV**, Varghese JJ, Kelley MP, Lam W, Lucore CL, Gill JB, Page L, Turner L, Davis C, Mikell FL; Stat Heart Investigators. Rural interhospital transfer of ST-elevation myocardial infarction patients for percutaneous coronary revascularization: the Stat Heart Program. *Circulation*. 2008 Mar 4;117(9):1145-1152. Epub 2008 Feb 11.

#### **BOOK REVIEWS AND BOOK CHAPTERS**

1. Sobel BE, Collen D (eds). *Coronary Thrombolysis in Perspective: Principles Underlying Conjointive and Adjunctive Therapy*. M Dekker, Inc., NY, Clinical Cardiol.
2. Kern MJ, Donohue TJ, Bach RG, Caracciolo EA, **Aguirre FV**. Update of clinical applications of the Doppler coronary flow velocity guidewire. In Kapoor AS (ed): "International Update on Interventional Cardiology", Kluwer Academic Publishers, Norwell, 1993.
3. **Aguirre FV**, Javier J. Manual of clinical problems in cardiology: with annotated key references. 5th ed (book review). *Circulation* 1996;93(2):388.
4. **Aguirre FV**. *Invasive Cardiology: Current Diagnostic and Therapeutic Issues* (book review). *J Invas Cardiol*; 1996.
5. **Aguirre FV**, Merritt RF. *Strategic Approaches in Coronary Intervention* (book review). *Circulation* ; 1996.
6. Colombo A, Hall P, Maiello L, Nakamura S, Gaglione A, **Aguirre FV**, Kern MJ. The interventional cardiac catheterization handbook, Chapter 5 - Stents - pgs 161-222.
7. **Aguirre FV**, Deligonul U, Kern MJ. The interventional cardiac catheterization handbook, Chapter 6 - Coronary atherectomy, rotational ablation and transluminal extraction catheter techniques. Stents - pgs 223-260.
8. Deligonul U, Kern MJ, Bach RG, Donohue TJ, Caracciolo EA, **Aguirre FV**, Talley JD. The cardiac catheterization handbook - third edition. Chapter 9 - Interventional techniques - pgs 501-566.
9. **Aguirre, FV**. Thrombolytics. American College of Cardiology CathSAP II, Basic Concepts in Cardiac Catheterization June 2001; 120-126.

#### **REQUESTED ARTICLES**

1. Kern MJ, **Aguirre F**, Donohue T, Bach R. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis. Coronary hemodynamics part III: Coronary hyperemia. *Cathet Cardiovasc Diagn* 1992;26:204-211.
2. Kern MJ, **Aguirre FV**, Hilton TC. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis. The effects of nitroglycerin. *Cathet Cardiovasc Diagn* 1992;25:241-248.
3. Kern MJ, **Aguirre FV**. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: pericardial compressive hemodynamics, Part I. *Cathet Cardiovasc Diagn* 1992;25:336-342.

4. Kern MJ, **Aguirre FV**. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: pericardial compressive hemodynamics, Part II. *Cathet Cardiovasc Diagn* 1992;26:34-40.
5. Kern MJ, **Aguirre FV**. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: pericardial compressive hemodynamics, Part III. *Cathet Cardiovasc Diagn* 1992;26:152-158.
6. Kern MJ, **Aguirre FV**. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: aortic regurgitation. *Cathet Cardiovasc Diagn* 1992; 26:232-240.
7. Kern MJ, **Aguirre F**. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: mitral valve gradients, part I. *Cathet Cardiovasc Diagn* 1992;26:308-315.
8. Kern MJ, **Aguirre F**. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: mitral valve gradients, part II. *Cathet Cardiovasc Diagn* 1992;27:52-56.
9. Kern MJ, **Aguirre F**, Donohue T. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: pressure wave artifacts. *Cathet Cardiovasc Diagn* 1992;27:147-154.
10. Kern MJ, Donohue T, Bach R, **Aguirre F**. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: cardiac arrhythmias. *Cathet Cardiovasc Diagn* 1992;27:223-227.
11. Kern MJ, **Aguirre F**, Donohue T, Bach R. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: adult congenital anomalies. *Cathet Cardiovasc Diagn* 1992;27:291-297.
12. Kern MJ, Donohue T, Bach R, **Aguirre F**. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: simultaneous left and right ventricular pressure measurements. *Cathet Cardiovasc Diagn* 1992;28:51-55.
13. Kern MJ, **Aguirre F**, Donohue T, Bach R. Hemodynamic rounds: interpretation of cardiac pathophysiology from pressure waveform analysis: Multivalvular regurgitant lesions. *Cathet Cardiovasc Diagn* 1993;28:167-172.
14. Kern MJ, Donohue TJ, Bach RG, Caracciolo EA, **Aguirre FV**. Clinical applications of the Doppler coronary flow velocity guidewire. *Cardio Interven* 1993;3:10-20.
15. Kern MJ, Donohue TJ, Bach RG, Caracciolo EA, Flynn MS, **Aguirre FV**. Clinical applications of the Doppler coronary flow velocity guidewire for interventional procedures. *J Interven Cardiol* 1993;6(4):345-363.
16. Kern MJ, Donohue TJ, Bach RG, Caracciolo E, **Aguirre FV**. Translesional flow velocity for lesion assessment. *Cathet Cardiovasc Diagn* 1993;30:265.
17. Talley JD, **Aguirre FV**. News & Views, Progress in Interventional Cardiology: acute myocardial infarction. *J Interven Cardiol* 1994;7(4):389-394.

18. Kern MJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ. Interventional physiology rounds: translesional pressure-flow velocity assessment in patients. *Cathet Cardiovasc Diagn* 1994;31:49-60.
19. Kern MJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ, Labovitz AJ. Interventional physiology rounds: fundamentals of translesional pressure-flow velocity measurements. *Cathet Cardiovasc Diagn* 1994;31:137-143.
20. Flynn MS, Kern MJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ. Interventional physiology rounds: Alterations in coronary blood flow velocity during intracoronary thrombolysis and rescue coronary angioplasty for acute myocardial infarction. *Cathet Cardiovasc Diagn* 1994;31:219-224.
21. Kern MJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ, Flynn MS, Moore JA. Interventional Physiology: Alterations of coronary flow velocity distal to coronary dissections before and after intracoronary stent placement. *Cathet Cardiovasc Diagn* 1994; 31:309-315.
22. Flynn MS, Kern MJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ. Interventional Physiology: Intramyocardial muscle bridging of the coronary artery: an examination of a diastolic "spike and dome" pattern of coronary flow velocity. *Cathet Cardiovasc Diagn* 1994;32:36-39.
23. Kern MJ, Caracciolo EA, **Aguirre FV**, Bach RG, Donohue TJ. Interventional physiology: Alterations of coronary flow velocity during intervention for acute myocardial infarction: responses to complications of intracoronary thrombolysis and angioplasty. *Cathet Cardiovasc Diagn* 1994;32:264-267.
24. Kern MJ, Bach RG, Donohue TJ, Caracciolo EA, **Aguirre FV**. Interventional physiology: Coronary stenoses with low translesional gradient and abnormal coronary reserve: physiologic results after angioplasty. *Cathet Cardiovasc Diagn* 1994;32:354-358.
25. Kern MJ, Donohue TJ, Flynn MS, **Aguirre FV**, Bach RG, Caracciolo EA. Interventional physiology: Limitations of translesional pressure and flow velocity for long ostial left anterior descending stenoses. *Cathet Cardiovasc Diagn* 1994;33:50-54.
26. Kern MJ, Bach RG, Donohue TJ, Caracciolo EA, **Aguirre FV**, Wolford T, Flynn MS, Moore JA. Interventional physiology: Role of large pectoralis branch artery to flow through a patent left internal mammary artery conduit. *Cathet Cardiovasc Diagn* 1995; 34:240-244.
27. Bach RG, Kern MK, Donohue TJ, Caracciolo EA, **Aguirre FV**, Moore JA. Interventional physiology: Dynamic systolic coronary flow reversal and hyperemia in left anterior descending coronary blood flow velocity during Valsalva maneuver in a patient with hypertrophic cardiomyopathy. *Cathet Cardiovasc Diagn* 1995;34:67-71.
28. Kern MJ, Bach RG, **Aguirre FV**, Caracciolo EA, Donohue TJ, Piek J. Interventional physiology: Collateral flow velocity alterations in the supply and receiving coronary arteries during angioplasty for total coronary occlusion. *Cathet Cardiovasc Diagn* 1995; 34:167-174.
29. Kern MJ, Donohue TJ, **Aguirre FV**, Bach RG, Caracciolo EA. Interventional physiology: assessment of circumflex artery stenoses before high-risk coronary angioplasty. *Cathet Cardiovasc Diagn* 1995;35:47-52.

30. al-Joundi B, Kern MJ, **Aguirre FV**, Donohue TJ, Moore JA, Flynn MS. Interventional physiology: Influence of intra-aortic balloon counterpulsation and collateral flow reversal during multivessel angioplasty. *Cathet Cardiovasc Diagn* 1995;35:149-158.
31. **Aguirre FV**, Merritt RF, Carollo SC. The role of coronary angiography after thrombolysis. *Current Opinion in Cardiol* 1995;10(4):381-388.
32. Kern MJ, **Aguirre FV**, Guerrero M. Hemodynamic rounds series II: abnormal hemodynamics after prosthetic aortic reconstruction: aortic stenosis or insufficiency? *Cathet Cardiovasc Diagn* 1998 Jul;44(3):336-40.

## ABSTRACTS

1. **Aguirre FV**, Lewen MK, Pearson AC, McClusky M, Labovitz AJ. Congestive heart failure in patients with normal left ventricular systolic function. *Clinical Research* 1987;35:256A.
2. **Aguirre FV**, Merkle EJ, Pearson AC, Lewen MK, Deligonul U, Labovitz AJ. Prognosis in patients with clinical congestive heart failure and normal left ventricular systolic function. *Eur Heart J* 1988;9(1):P1730A.
3. Gudipati C, Deligonul U, Kern M, **Aguirre F**, Serota H, Lew B, Vandormael M. Comparison of regional coronary vasodilatory reserve between normal and post angioplasty arteries in the same patient. *J Am Coll Cardiol* 1989;13:188A.
4. Pearson AC, **Aguirre F**, Mrosek D, Nelson J, Kern M, Labovitz A. A comparison of the accuracy and efficiency of color flow to conventional Doppler echocardiography for quantitating aortic and mitral insufficiency. XIth Congress European Society Cardiol - Presented 9/89.
5. Vandormael M, Deligonul U, Kern M, **Aguirre F**, Serota H, Lew B, Taussig S. Long-term (;4 years) followup after coronary angioplasty in multivessel disease. *Eur Heart J* 1989;10:1.
6. Serota H, Deligonul U, Lee W, **Aguirre F**, Kern MJ, Vandormael M. Predictors of early (,6 months) mortality after PTCA in patients with severe left ventricular dysfunction. *Circulation* 1989;80:II-480.
7. Younis LT, Carraci BF, Dowel S, **Aguirre FV**, Byers SL, Barth G, Peterson GJ, Chaitman BR. Two year prognosis after IV dipyridamole thallium imaging in patients with peripheral vascular disease. *Circulation* 1989;80:II-904.
8. **Aguirre F**, Serota H, Janosik D, Thornton T, Major M, Kern M, Deligonul U, Chaitman B. Reduced late potentials after myocardial infarction in patients with patent infarct artery. *Eur Heart J* 1990;II:388.
9. Kern MJ, Deligonul U, Serota H, **Aguirre F**, Ring ME, Gudipati C. Equivalency of intravenous adenosine and papaverine for determination of coronary flow velocity reserve in patients. *Eur Heart J* 1990;II:13.
10. **Aguirre F**, Calliccoat P, Pedersen W, Serota H, Deligonul U, Kern M. Beneficial effects of a low-osmolar contrast agent in high risk patients undergoing coronary angiography. *Eur Heart J* 1990;II:292.

11. Kern MJ, Talley JD, Deligonul U, Vandormael M, Serota H, **Aguirre M**, Gudipati C, Ring M, Joseph A, Yussman ZA. Preliminary experience with 5F angiographic catheter as guiding catheter for coronary angioplasty. *Soc Cardiac Angio* 1990;19:295.
12. Castello R, Lenzen PM, **Aguirre FV**, Labovitz AJ. Quantitative comparison of transthoracic and transesophageal echocardiography in the evaluation of mitral regurgitation. *Circulation* 1990;82:III-550.
13. Hsia J, Kleiman NS, **Aguirre F**, Roberts R, Chaitman B, Ross AM. Angiographic predictors of reocclusion following initially successful thrombolysis. *Circulation* 1990; 82:III-255.
14. Serota H, **Aguirre F**, Seiler S, Barner H, Kennedy H. Improved early and late graft patency and postoperative bleeding complication rates in patients treated with dipyridamole and aspirin undergoing coronary bypass surgery. *Circulation* 1990;82:III-361.
15. Kern MJ, Deligonul U, Tatineni S, Serota H, **Aguirre F**, Hilton T. Equivalency of intravenous adenosine to intracoronary papaverine for determination of coronary flow velocity reserve in patients. *Circulation* 1990;82:III-300.
16. Ofili E, Karim A, Kern MJ, Deligonul U, **Aguirre F**, Serota H, Tatineni S. Simultaneous comparison of intracoronary spectral and zero cross flow velocity measurements by Doppler angioplasty guidewire and catheter technique. *J Am Coll Cardiol* 1991;17:124A.
17. Kern MJ, Deligonul U, Serota H, **Aguirre F**, Tatineni S, Hilton T. Use of low dose intravenous bolus adenosine for determination of coronary vasodilatory reserve in patients. *J Am Coll Cardiol* 1991;17:283A.
18. Chaitman BR, Kern MJ, Taylor HA, **Aguirre FV**, Sopko G, Ross RN, Bovill EC and TIMI investigators. Does one-year outcome after acute myocardial infarction differ with race? Results from the TIMI II trial. *J Am Coll Cardiol* 1991;17:246A.
19. **Aguirre FV**, Serota H, McMahon RP, Sopko G, Solomon RE, Chaitman BR, Braunwald E, and TIMI investigators. Prognosis of patients without myocardial necrosis after thrombolytic therapy: a TIMI II data bank study. *J Am Coll Cardiol* 1991;17:228A.
20. **Aguirre FV**, Kern MJ, Berger PB, McMahon RP, Sopko G, Ross AM, Chaitman BR, TIMI II investigators. Comparison of left ventricular function and clinical outcome in patients developing Q-wave and non-Q-wave myocardial infarction after thrombolysis: TIMI II databank study. *Circulation* 1991;84:II-231.
21. **Aguirre FV**, Mueller H, Kleiman N, McMahon R, Solomon R, Kern MJ, Chaitman BR, TIMI II investigators. Clinical outcome of young patients with acute myocardial infarction treated with thrombolytic therapy: is a "watchful waiting" strategy appropriate? A TIMI II databank study. *Circulation* 1991;84:II-231.
22. Hsia J, Kleiman N, **Aguirre F**, Chaitman BR, Roberts R, Ross AM. Heparin-induced partial thromboplastin time after thrombolysis: prolongation magnitude determinations of coronary patency. *Circulation* 1991;84:II-116.

23. Kern MJ, Segal J, Ofili E, Heuser R, Scott N, **Aguirre F**, St. Vrain J, Labovitz A, FLOMAP study group. A new method for quantitating coronary collateral flow in patients during coronary angioplasty using the Doppler guidewire. *Circulation* 1991;84:II-293.
24. Kern MJ, **Aguirre F**, Penick D, Tatineni S, Hilton TC. Enhanced intracoronary flow velocity during intra-aortic balloon counterpulsation in patients with coronary artery disease. *Circulation* 1991;84:II-485.
25. Miller DD, Donohue TJ, Byers SL, Bach RG, **Aguirre FV**, Younis LT, Wittry MD, Goodgold HM, Chaitman BR. Adenosine technetium-99m sestamibi myocardial tomographic correlates of post-stenotic intracoronary Doppler flow reserve: preliminary evidence against a hyperemic "roll-off" in tracer extraction in man. *Circulation* 1992;86: I-506.
26. Miller DD, Craig FE, Dressler FA, Farrar MA, Breland CM, Bach RG, Donohue TJ, Chaitman BR, **Aguirre FV**. Immunohistochemical characterization of the lymphoid/ mononuclear cell composition of human atherectomy tissue: correlation with interleukin-2 receptor expression. *Circulation* 1992;86:I-800.
27. Kleiman NS, Ohman EM, Ellis SG, **Aguirre FV**, Weisman H, Schaible T for the TAMI 8 investigators. Infarct vessel patency is enhanced by profound platelet inhibition with fibrinogen receptor blockade with 7E3 in patients receiving thrombolysis for acute myocardial infarction. *Circulation* 1992;87:I-260.
28. Donohue TJ, Kern MJ, **Aguirre FV**, Bell C, Penick D, Segal J, Ofili E, Heuser R. Determination of the hemodynamic significance of angiographically intermediate coronary stenoses by intracoronary doppler flow velocity. *J Am Coll Cardiol* 1992;19:242A.
29. Donohue TJ, Kern MJ, **Aguirre FV**, Bell C, Penick D, Ofili E. Comparison of hemodynamic and pharmacologic perturbations of coronary collateral flow velocity in patients during angioplasty. *J Am Coll Cardiol* 1992;19:383A.
30. Bach RG, Donohue T, **Aguirre F**, Bell C, Penick D, Kern MJ. Comparison of compliant and noncompliant balloons on the outcomes of coronary angioplasty. *Cathet Cardiovasc Diagn* 1992;26:73.
31. Kern MJ, **Aguirre F**, Donohue T, Bach R, Bell C, Wolford T, Penick D. Augmentation of coronary blood flow velocity during intra-aortic balloon pumping after coronary angioplasty with a Doppler guidewire. *Cathet Cardiovasc Diagn* 1992;26:77.
32. Kern MJ, **Aguirre F**, Donohue T, Bach R, Bell C, Wolford T, Penick D. Augmentation of coronary blood flow velocity during intra-aortic balloon pumping after coronary angioplasty with a Doppler guidewire. *Eur Heart J* 1992;13:32.
33. Bach RG, Kern MJ, Donohue T, **Aguirre F**, Penick D. Comparison of arterial and venous coronary bypass conduits: analysis of intravessel blood flow velocity characteristics. *Circulation* 1992;86:I-181.
34. Donohue TJ, Kern MJ, Bach RG, **Aguirre F**, Bell C, Wolford T, Penick D. Transstenotic pressure gradient-flow velocity relationships in patients with coronary artery disease. *Circulation* 1992;86:I-855.

35. Mechem CJ, Kern MJ, **Aguirre F**, Cauley M, Stonner T. Safety and outcome of angioplasty guidewire Doppler instrumentation in patients with normal or mildly diseased coronary arteries. *Circulation* 1992;86:I-323.
36. Donohue T, Kern MJ, Miller DD, Bach R, Labovitz AJ, Chaitman BR, Caracciolo E, **Aguirre FV**. Improved decision making for coronary interventions: comparison of intracoronary lesion flow dynamics versus ischemic stress testing. *J Am Coll Cardiol* 1993;21:152A.
37. **Aguirre FV**, Werth D, Gudipati CV, Pedersen W, Lewen M, Wise NK, Changlani M, Al-Joundi B, Flynn M, Stonner T, Kern MJ, Chaitman B. Factors limiting effective heparinization following thrombolysis for acute myocardial infarction: interim findings from the t-PA-heparin duration trial. *J Am Coll Cardiol* 1993;21:136A.
38. Younis L, Kern MJ, Bach R, Donohue T, **Aguirre FV**, Mechem C, Cauley M, Stonner T. Post-procedural normalization of coronary flow dynamics following successful atherectomy, PTCA and stenting: analysis by intracoronary spectral Doppler. *J Am Coll Cardiol* 1993; 21:79A.
39. al-Joundi B, Kern MJ, Donohue T, Bach R, **Aguirre FV**, Chaitman BR, Miller DD. Is intravenous dipyridamole coronary hyperemia reversal by aminophylline equivalent to adenosine cessation? Comparison using continuous intracoronary spectral flow velocity measurements. *J Am Coll Cardiol* 1993;21:420A.
40. **Aguirre F**, Werth D, Gudipati CV, Gibson P, Pedersen W, Lewen M, Serota H, Johnson W, Armbruster R, Al-Joundi B, Flynn M, Stonner T, Nemeth M, Kern MJ, Chaitman B for the study group. Optimal duration of heparinization following thrombolytic therapy for acute myocardial infarction: interim results of the multicenter randomized t-PA heparin duration study. *Eur Heart J* (Accepted 1993).
41. **Aguirre F**, Werth D, Gudipati CV, Gibson P, Pedersen W, Johnson WB, Lewen M, Hamilton W, Al-Joundi B, Flynn M, Armbruster R, Stonner T, Chaitman b for t-PA heparin trial investigators. Influence of intravenous heparin duration on clinical outcome of patients receiving accelerated weight-adjusted rt-PA for acute myocardial infarction: preliminary results of the multicenter randomized t-PA heparin duration trial. *Circulation* 1993;88(4):I-201.
42. **Aguirre F**, Ferguson JJ, Califf RM for the EPIC study group. Clinical predictors of bleeding complications in high risk angioplasty patients: results from the EPIC study group. *Circulation* 1993;88(4):I-252.
43. Flynn M, Werth D, Gudipati R, Pedersen W, Serota H, Johnson WB, Gibson P, Hamilton W, Morton D, Changlani M, Armbruster R, Stonner T, Al-Joundi B, Lewen M, **Aguirre F** for the rt-PA heparin duration trial investigators. Influence of heparin duration on coronary angiographic characteristics in patients receiving accelerated weight-adjusted rt-PA dosing for acute myocardial infarction. *Circulation* 1993;88(4):I-201.
44. Kern M, Donohue T, Bach R, **Aguirre F**, Caracciolo E, Mechem C, Cauley M, Flynn M, Chaitman B. Clinical outcome of deferred angioplasty in patients based on normal translesional pressure-flow velocity measurements. *Circulation* 1993;88(4):I-204.

45. Dressler FA, Miller DD, **Aguirre FV**, Farrar MA, Breland CM, Yip D, Stonner T, Bach RG, Donohue TJ, Bell C, Gibson P, Mooney J, Mooney MR for the Midwest Atherectomy Research Group (MARG). Quantitative histomorphometry of cellularity and matrix synthesis in primary and restenotic coronary atherectomy specimens. *Circulation* 1993;88(4):I-651.
46. Kern MJ, Donohue T, Bach RG, Caracciolo E, **Aguirre FV**, Mechem C, Cauley M. Hemodynamic significance of coronary jet velocity in patients with angiographically intermediately severe lesions. *Cathet Cardiovasc Diagn* 1993;29:89.
47. Kern MJ, Bach RG, Donohue TJ, Caracciolo EA, **Aguirre FV**, Mechem C, Cauley M, Abbott L. Clinical utility of continuous coronary flow velocity monitoring during interventional studies. *Cathet Cardiovasc Diagn* 1993;29:81.
48. Kern MJ, Al-Joundi B, Donohue TJ, Bach RG, Caracciolo EA, **Aguirre FV**, Chaitman BR, Miller DD. Reversal of dipyridamole-induced coronary hyperemia by aminophylline: and analysis by continuous quantitative intracoronary spectral flow velocity. *Cathet & Cardiovasc Diagn* 1993;29:81.
49. Kern MJ, Al-Joundi B, Donohue TJ, Bach RG, Caracciolo EA, **Aguirre FV**. Reversal of dipyridamole-induced coronary hyperemia by aminophylline: analysis by continuous quantitative intracoronary spectral flow velocity. *Eur Heart J* 1993;14:46.
50. Donohue TJ, Bach RG, Caracciolo EA, Wolford T, Kern MJ, **Aguirre FV**, Marilyn Cauley M. Quantitation of coronary collateral flow velocity by anatomic pathway in patients. *J Am Coll Cardiol* February, 1994:415A.
51. Kern MJ, Anderson HV, Talley JD, Caracciolo EA, Bach RG, Donohue TJ, **Aguirre FV**, Moore JA, Flynn MS, Segal J, Mechem CJ, Cauley M, Stikovac M. Relationship of post-procedural distal coronary flow dynamics with restenosis after coronary angioplasty: results of a multicenter pilot study. *J Am Coll Cardiol* February, 1994:137A.
52. Moore JA, Kern MJ, Donohue TJ, Bach RG, Caracciolo EA, **Aguirre FV**, Flynn MS. Distal coronary flow velocity and physiology during direct angioplasty for acute myocardial infarction in patients. *J Am Coll Cardiol* February, 1994:243A.
53. Kern MJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ, Moore JA, Flynn MS, Mechem CJ, Cauley M, Labovitz AJ. Comparison of intralésional Doppler flow velocity and quantitative angiography for determination of translesional pressure gradients in patients. *J Am Coll Cardiol* February, 1994:174A.
54. Bach RG, Al-Joundi B, Kern MJ, Donohue TJ, Caracciolo E, **Aguirre FV**, Wolford T, Miller DD. High dose dipyridamole compared with standard infusion fails to further augment coronary hyperemia in patients. *J Am Coll Cardiol* February, 1994:127A.
55. Dressler FA, **Aguirre FV**, Farrar MA, Breland CM, Yip D, Stonner T, Bach RG, Donohue TJ, Kern MJ, Bell C, Gibson P, Mooney J, Mooney MR, Miller DD. Quantitative histomorphometric analysis of vascular cellularity and matrix synthesis in primary and restenotic coronary directional atherectomy specimens. *Restenosis Summit V*, 1993:27.

56. Tron C, Kern M, Donohue T, Bach R, **Aguirre F**, Caracciolo E. Correlations between quantitative coronary angiography derived and directly measured translesional physiology. *Eur Heart J* 1994;15:384(P2007).
57. Kern M, **Aguirre F**, Bach R, Donohue T, Caracciolo E, Drury J. Variations in normal coronary vasodilatory reserve by artery, sex and status post transplantation. *Eur Heart J* 1994;15:353(1873).
58. Bach RG, Kern MJ, Donohue TJ, **Aguirre FV**, Caracciolo EA, Flynn MS, Wolford T. Correlation of intracoronary flow velocity with subsequent stent restenosis. *Cathet Cardiovasc Diagn* 1994;32:92(#P23).
59. Tron C, Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA. Assessment of translesional coronary hemodynamics: comparison of quantitative angiographic parameters with direct pressure and flow measurements in patients. *Cathet Cardiovasc Diagn* 1994; 32:86(#17).
60. Moore JA, Kern MJ, Donohue TJ, Bach RG, Caracciolo EA, **Aguirre FV**, Flynn MS. Disparity of TIMI grade flow and directly measured coronary flow velocity during direct angioplasty for acute myocardial infarction. *Cathet Cardiovasc Diagn* 1994;32:86(#18).
61. Donohue TJ, Kern MJ, Bach RG, Miller DD, Caracciolo EA, Wolford TL, Cauley M, **Aguirre FV**. Post stenotic coronary flow reserve, transstenotic gradient, and stress perfusion imaging: physiologic correlations of coronary stenosis severity. *Cathet Cardiovasc Diagn* 1994;32:85(#16).
62. Tron C, Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Moore JA, Cauley MB, Miller DD. Comparison of post-stenotic flow velocity reserve and translesional pressure-derived fractional flow reserve for prediction of myocardial perfusion imaging results. *Circulation* 1994;90(4):I-226.
63. Kern MJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ, Wolford T, Moore JA, Miller LW. Variations in coronary vasodilatory reserve by artery, sex, status post transplantation, and remote coronary disease. *Circulation* 1994;90(4):I-154.
64. **Aguirre FV**, Topol EJ, Donohue TJ, Kern MJ, Leimberger JD, Califf RM, for the EPIC investigators. Impact of ionic and non-ionic contrast media on post-PTCA ischemic complications: results from the EPIC trial. *J Am Coll Cardiol* February, 1995:8A.
65. **Aguirre FV**, Donohue TJ, Bach RG, Caracciolo EA, Moore JA, Wolford T, Khoury A, Mechem C, Kern MJ. Coronary flow velocity of infarct-related arteries: physiologic differences between complete (TIMI III) and incomplete (TIMI 0,I,II) angiographic coronary perfusion. *J Am Coll Cardiol* February 1995:401A.
66. Bach RG, Donohue TJ, Caracciolo EA, **Aguirre FV**, Wolford T, Kern MJ. Intraaortic balloon pumping augments distal coronary blood flow provided through perfusion balloon catheters during high risk PTCA. *J Am Coll Cardiol* February, 1995:150A.
67. Miller DD, Esparza J, Shah LJ, Mechem c, Byers SL, **Aguirre FV**, Goodgold HM, Kern MJ, Donohue TJ. Prognostic value of technetium-99m sestamibi myocardial tomography one month after successful angioplasty: comparison to peri-procedural angiographic and intracoronary Doppler flow velocity parameters. *J Am Coll Cardiol* February 1995:29A.

68. Khoury A, Donohue T, Bach R, Caracciolo E, **Aguirre F**, Wolford T, Kern M. Alterations in coronary blood flow after adjunctive percutaneous transluminal coronary angioplasty during rotational atherectomy. *Eur Heart J* 1995;61:482 (P2774).
69. Dolan MS, Castello R, Kern MJ, **Aguirre FV**, Bach RG, Caracciolo EA, Donohue TJ, Dressler FA, Mechem CJ, Vaughn LM, St. Vrain JA, Labovitz AJ. Dobutamine stress echocardiography in evaluation of coronary stenosis: correlation of systolic wall thickening and post-stenotic coronary blood flow. *Circulation* 1995;92(8):I-478.
70. Kern MJ, **Aguirre FV**, Donohue TJ, Bach RG, Caracciolo EA, Wolford TL, Khoury A, Mechem C. Impact of residual lumen narrowing on coronary flow after angioplasty and stent: intravascular ultrasound Doppler and imaging data in support of physiologically-guided coronary angioplasty. *Circulation* 1995;92(8):I-263.
71. **Aguirre FV**, Ferguson JJ, Blankenship JC, Pieper KS, Taylor M, Harrington RA, Rund M, Caracciolo EA, Donohue TJ, Califf RM, Lincoff AM, Tcheng JE, Topol EJ, for the IMPACT-II Investigators. Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: results from the IMPACT-II Trial. *J Am Coll Cardiol* 1996;27:83A.
72. Bach RG, Wolford T, Donohue TJ, Drury JH, Caracciolo EA, **Aguirre FV**, Kern MJ, Miller LW. Cardiac allograft microvascular dysfunction correlates with a peripheral marker of immunocyte activation. *J Am Coll Cardiol* 1996;27:206A.
73. Ferguson JJ, McDounogh TJ, Worley SJ, French WJ, Corbelli JC, Blankenship JC, Carey D, **Aguirre FV**, Harrington RA, Talley JD. Clinical outcome of "high-risk" versus "elective" patients undergoing percutaneous coronary intervention: results from IMPACT-II. *J Am Coll Cardiol* 1996;27:180A.
74. Blankenship JC, Mandak JS, **Aguirre FV**, Berkowitz SD, Gilchrist IC, Sheikh KH, Griffin JJ, McIvor ME, Resar JR, Weiner BH. Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II Trial. *J Am Coll Cardiol* 1996;27:360A.
75. Steinhubl SR, Moliterno DJ, Teirstein PS, Guarneri EM, **Aguirre FV**, Ferguson JJ, Perin EC, Strickman N, Kereiakes D, Tcheng JE, Ellis SG, Topol EJ. Stenting for acute myocardial infarction: the early United States multicenter experience. *J Am Coll Cardiol* 1996;27:279A.
76. Dolan MS, Bach RG, Castello R, St. Vrain JA, Mechem CJ, Vaughn LM, Donohue TJ, **Aguirre FV**, Dressler FA, Kern MJ, Labovitz AJ. Effect of beta-blockers on coronary blood flow and left ventricular function during dobutamine-induced acute ischemia. XVIIIth Congress of European Society of Cardiology (Accepted).
77. **Aguirre FV**, Topol EJ, Ferguson JJ, Blankenship JC, Gardner LH, Caracciolo EA, Donohue TJ, Harrington RA, Tcheng JE, for the IMPACT-II Investigators. Effect of platelet glycoprotein (GP) IIb/IIIa antagonism with integrilin on activated clotting times during coronary interventions: results from the IMPACT-II trial. *Circulation* 1996;94: I-197.
78. **Aguirre FV**, Talley DJ, Ferguson JJ III, Tcheng J, Kleiman NS, Montague EA, Booth JE, Lincoff AM. Efficacy of abciximab, despite patient weight, using lower heparin dosing during percutaneous coronary interventions. *Circulation* 1996;94:I-198.

79. Moliterno DJ, **Aguirre FV**, Cannon CP, Every NR, Granger CB, Sapp SK, Booth J, Gerguson JJ, for the GUARANTEE investigators. The global unstable angina registry and treatment evaluation ( GUARANTEE) study. *Circulation* 1996;94:I-195.
80. Cannon CP, Ferguson JJ, Every N, Anderson HV, **Aguirre FV**, Granger CB, French WJ, Sapp S, Booth JE, Moliterno DJ, for the GUARANTEE Investigators. AHot@ unstable angina - is it worse than subacute unstable angina? Results from the GUARANTEE registry. *J Am Coll Cardiol* 1997;29 (#2, suppl A):489A.
81. Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Wolford TL. Assessment of intermediate coronary stenosis by relative coronary flow velocity reserve. *J Am Coll Cardiol* 1997;29(#2, suppl A):21A.
82. Cannon CP, Moliterno D, Every N, Anderson HV, **Aguirre FV**, Granger CB, Lambrew CT, Rabbani LE, Arnold A, Scirica BM, Sapp S, Booth JE, Ferguson JJ for the GUARANTEE Investigators. Implementation of AH CPR guidelines for unstable angina in 1996: unfortunate differences between men and women: results from the multicenter GUARANTEE registry. *J Am Coll Cardiol* 1997;29 (#2, suppl A):217A
83. Thel MC, Davidson CJ, **Aguirre FV**, Peck S, Tchong JE, Lincoff AM, Topol EJ, Califf RM for the IMPACT II investigators. What predicts contrast nephropathy after coronary intervention? Insights from the IMPACT II trial. *J Am Coll Cardiol* 1997;29(#2, suppl A):500A.
84. Miller DD, Nallamothu RB, Shaw LJ, Byers S, Mechem C, Kern MJ, **Aguirre FV**. Does intracoronary Doppler assessment of post-stenotic reperfusion flow enhance cardiac event prediction as compared to other post-myocardial infarction risk markers? *J Am Coll Cardiol* 1997;29(#2, suppl A):71A.
85. **Aguirre FV**, Topol EJ, Leimberger J, Kleiman N, Lincoff AM, Donohue TJ, Califf RM. Incidence and clinical outcome of abrupt vessel closure among patients receiving abciximab during high-risk percutaneous coronary intervention: EPIC trial results. *J Am Coll Cardiol* 1997;29(#2, suppl A):394A.
86. Kleiman NS, Lincoff AM, Miller DP, **Aguirre FV**, Weisman H, Cabot C, Califf RM, Topol EJ. Abciximab (c7E3) reduces death and myocardial infarction but not target vessel revascularization in diabetics undergoing percutaneous transluminal coronary angioplasty: the EPILOG experience. *European Society of Cardiology (Submitted 2/97)*.
87. **Aguirre FV**, Simoons ML, Ferguson JJ, Fitzpatrick SE, Anderson KM, Kern MJ, Tchong JE. Impact of contrast media on clinical outcome following percutaneous coronary interventions with platelet glycoprotein IIb/IIIa inhibition: meta-analysis of clinical trials with abciximab. *American Heart Association 70<sup>th</sup> Scientific Sessions (Submitted 5/97)*.
88. Kern, MJ, Puri S, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Wolford TL. Role of relative flow velocity reserve in determining an endpoint for coronary artery stenting. *American Heart Association 70<sup>th</sup> Scientific Sessions (Submitted 5/97)*.

89. Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Wolford TL, Craig WR, Mechem CJ, Dolan M, Labovitz AJ. Comparison of relative coronary flow velocity reserve to ischemic stress testing in patients with an intermediate coronary stenosis. American Heart Association 70<sup>th</sup> Scientific Sessions (Submitted 5/97).
90. Cannon CP, Scirica BM, Every NR, Anderson HV, **Aguirre FV**, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ. Racial differences in the management of unstable angina: results from the GUARANTEE registry. *Circulation* 1997;96:I-596.
91. Kleiman NS, Lincoff AM, **Aguirre FV**, Kereiakes DJ, Miller DP, Cabot CF, Andersen K, Topol EJ. Should diabetics treated with abciximab receive more heparin than non-diabetics? Findings of a multicenter trial. *Circulation* 1997;96:I-386.
92. Blankenship JC, Anderson KM, Demko SL, Cabot CF, Kereiakes DJ, **Aguirre FV**. Decreased vascular access site bleeding after coronary intervention with abciximab in the EPILOG vs the EPIC trial. *Circulation* 1997;96:I-161.
93. Stikovac MM, Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Craig WR, Bitar S, Mechem C. Threshold value and accuracy in intracoronary relative coronary flow reserve in patients with coronary artery disease. Poster presentation Am College Cardiol 47<sup>th</sup> Scientific Sessions
94. Stikovac MM, Kern MJ, Donohue TJ, Bach RG, **Aguirre FV**, Caracciolo EA, Craig WR, Bitar S, Mechem C. Additive value of relative coronary flow reserve in the assessment of intermediate coronary artery stenosis: comparison to myocardial stress perfusion imaging. Poster presentation Am College Cardiol 47<sup>th</sup> Scientific Sessions
95. Scirica BM, Moliterno DJ, Every NR, Anderson V, **Aguirre FV**, Granger CB, Lambrew CT, Rabbani LE, Arnold A, Sapp S, Booth JE, Ferguson JJ, Cannon CP and the GURANTEE Investigators. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry).
96. Lucore CL, **Aguirre FV**, Rocha-Singh KJ, Ligon RW, Mishkel GJ. Prairie Cardiovascular Consultants, Ltd. Springfield, IL. Implications of the changing spectrum of PCI for acute myocardial infarction in a community practice. (Poster abstract, TCT 9/22-26/99, Washington, DC)
97. **Aguirre FV**, Mishkel GJ, Rocha-Singh KJ, Gill JB, Kacich, RL, Moses HW, Mikel FL, Mayer SA, Mallavarapu CT, Lucore CL, Lam W, Shelton ME, Steen MS, Trask RV, Yakel D. Comparison of Platelet Inhibition Achieved with Abciximab vs Eptifibatide During Percutaneous Coronary Intervention: Influence of Platelet Inhibition on Clinical Outcomes. (Poster abstract XXII EOS Annual Congress: 8/26-30/2000, Amsterdam, Netherlands)
98. **Aguirre FV**, Mishkel GJ, Rocha-Singh KJ, Gill JB, Kacich, RL, Moses HW, Mikel FL, Mayer SA, Mallavarapu CT, Lucore CL, Lam W, Shelton ME, Steen MS, Trask RV, Yakel D. In-hospital and 30-day economic and clinical outcomes with platelet GP IIb/IIIa ReoPro vs Integrilin therapy during percutaneous coronary intervention (PRICE) trial. Abstract, oral presentation AHA, 11/12-15/2000, New Orleans, LA

99. **Aguirre FV**, Mishkel GJ, Rocha-Singh KJ, Gill JB, Kacich, RL, Moses HW, Mikel FL, Mayer SA, Mallavarapu CT, Lucore CL, Lam W, Shelton ME, Steen MS, Trask RV, Yakel D. Comparison of platelet inhibition achieved with abciximab vs eptifibatide during percutaneous coronary intervention: Influence of platelet inhibition on clinical outcome. (Poster abstract, American Heart Association, 11/12-15/2000, New Orleans, LA)
100. **Aguirre FV**, Mishkel GJ, Singh, IV, Mayer, SA, Gill JB, Shelton ME, Yakel D, Lam W, Mallavarapu CT, Antezano E, Kodali D, Holloway C. Overestimation of tirofiban-mediated platelet inhibition during percutaneous coronary intervention: Impact of sodium citrate anticoagulation. (Poster abstract, AHA, 11/12-15/2000, New Orleans, LA).
101. Mishkel G, MD, Goswami N, MD, Gill J, MD, **Aguirre F, MD**, Ligon R, MS, Moore A, BS. Treatment of In-Stent Restenosis in the Era of Drug Eluting Stents: The Rise and Fall of Brachytherapy. Abstract poster presentation, ACC 2005.
102. Mishkel G, MD, Goswami N, MD, Gill J, MD, **Aguirre F, MD**, Ligon R, MS, Moore A, BS. A "Real World" Evaluation of Drug Eluting Stents in Saphenous Vein Grafts. Abstract submitted and accepted ACC 2005.
103. Mishkel G, MD, **Aguirre F, MD**, Gill J, MD, Lucore C, MD, Ligon R, MS, Moore A, BS. Drug Eluting Stents vs. Bare Metal Stents for the Treatment of ST-Segment Elevation Myocardial Infarction. *Am J Cardiol.* 2004;94(suppl 6A):12E.
104. Varghese J, MD, Khalid O, MD, Davis C, Page L, RN, Kelley M, MD, Lam W, MD, Mikell F, MD, **Aguirre F, MD**. Transfer Program Eliminates Inappropriate Fibrinolytic Therapy in Patients with Presumed Acute ST Elevation Myocardial Infarction. Abstract, TCT 2006.
105. **Aguirre F, MD**, Varghese J, MD, Kelley M, MD, Lam W, MD, Gill J, MD, Lucore C, MD, Page L, RN, Kabbes D, MD, Pinter L, MD, Ferguson R, RN, Weber K, RN, Mikell F, MD. Treatment and Transport Limitations Associated with Inter-Hospital Transfer Strategies for ST Elevation Myocardial Infarction: One Shoe Does Not Fit All. Abstract submitted and accepted AHA 2006.
106. **Aguirre F, MD**, Varghese J, MD, Whitmore M, MD, Page L, RN, Coop K, RN, Lam W, MD, Kelley M, MD, Mikell, F, MD. Factors Influencing Door-to-Perfusion Times in ST Elevation Myocardial Infarct Patients Transferred for Primary Percutaneous Coronary Intervention: Impact of Pre-hospital ECG Diagnosis. Abstract submitted and accepted AHA 2006.
107. Joji J. Varghese, **Frank V. Aguirre**, Syeda Rumman, Sushma Koneru, David L. Griffen, Jayne Thompson, Karen Baur, Gary Mangold, Jack Gruwell, Conrad Davis, John B Gill, Wilfred, Lam, Michael P. Kelley, Frank L. Mikell. ACC.07 Abstract: Impact of Coordinated Process of Care on Individual Components of Treatment Delays Among ST Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention. ACC.07 56<sup>th</sup> Annual Scientific Session. March 24-27-2007, **New Orleans**.
108. **Frank V. Aguirre**, Joji Varghese, Michael P Kelley, Wilfred Lam, John B. Gill, Charles L Lucore, Lisa Page, Doug Kabbes, Larry Pinter, Rebecca Ferguson, Kate Weber, Frank Mikell. Treatment and transport Limitations Associated with Inter-Hospital Transfer Strategies for ST Elevation Myocardial Infarction: One Shoe Does Not Fit All . Abstract published in Circulation Scientific Sessions 2006; Vol 114 NO 18 October 31, 2006; II-420.

Frank V. Aguirre, M.D.

109. **Frank V. Aguirre**, Joji Varghese, Michael Witmore, Lisa Page, Kaye Coop, Wilfred Lam, Michael P. Kelley, Frank L Mikell. Factors Influencing Door-to-Perfusion Times in ST Elevation Myocardial Infarct Patients Transferred for Primary Percutaneous Coronary Intervention: Impact to Pre-hospital ECG Diagnosis. Abstract published in Circulation Scientific Sessions 2006; Vol 114 NO 18 October 31, 2006; II-420.
110. **Aguirre FV**, Varghese J, Agarwal A, Turner L, Page L, Friedrich S, Thompson J, Tebrugge D, Lam W, Kelley M, Mikell F. Coordinated Inter-Hospital Transfer Program Improves the Quality of Care Delivered to ST Elevation Myocardial Infarction Patients Presenting in Rural Communities. ACC.08 57<sup>th</sup> Scientific Session. March 29-April 1, 2008, Chicago.
111. Varghese J, Rumman S, Koneru S, Berrio G, Baur K, Markwell S, Griffen D, Mikell F, **Aguirre FV**. Coordinated ST-Elevation Myocardial Infarction Process of Care Eliminates Off Hour Variations of Door-to-Balloon Times. ACC.08 57<sup>th</sup> Scientific Session. March 29-April 1, 2008, Chicago.